eGenesis, Inc.’s Post

📃Scientific paper: Antiemetic effects of baclofen in a shrew model of postoperative nausea and vomiting: Whole‐transcriptome analysis in the nucleus of the solitary tract Abstract: AIMS: The molecular genetic mechanisms underlying postoperative nausea and vomiting (PONV) in the brain have not been fully elucidated. This study aimed to determine the changes in whole transcriptome in the nucleus of the solitary tract (NTS) in an animal model of PONV, to screen a drug candidate and to elucidate the molecular genetic mechanisms of PONV development. METHODS: Twenty‐one female musk shrews were assigned into three groups: the Surgery group (shrew PONV model, n = 9), the Sham group (n = 6), and the Naïve group (n = 6). In behavioral studies, the main outcome was the number of emetic episodes. In genetic experiments, changes in the transcriptome in the NTS were measured. In a separate study, 12 shrews were used to verify the candidate mechanism underlying PONV. RESULTS: A median of six emetic episodes occurred in both the Sham and Surgery groups. Whole‐transcriptome analysis indicated the inhibition of the GABA(B) receptor‐mediated signaling pathway in the PONV model. Baclofen (GABA(B) receptor agonist) administration eliminated emetic behaviors in the shrew PONV model. CONCLUSIONS: Our findings suggest that the GABA(B) receptor‐mediated signaling pathway is involved in emesis and that baclofen may be a novel therapeutic or prophylactic agent for PONV. Continued on ES/IODE ➡️ https://etcse.fr/Ck8j ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

🧬🐖 Can genetically modified animal organs solve the global organ shortage crisis? 📅 On January 7, 2022, history was made when David Bennett received a pig heart in a groundbreaking xenotransplantation surgery. This innovative procedure offers a glimmer of hope amidst the organ shortage crisis, where over 100,000 individuals anxiously await life-saving transplants, with 17 potentially losing their battle today alone. Xenotransplantation, the transplantation of genetically modified animal organs with human genes, is emerging as a promising solution to this global healthcare challenge. Explore this extraordinary story and the potential it holds for the future of medical innovation. 👇 #transplant #crispr #geneediting #organshortage https://lnkd.in/dmsgjCNS

📃Scientific paper: Antiemetic effects of baclofen in a shrew model of postoperative nausea and vomiting: Whole‐transcriptome analysis in the nucleus of the solitary tract Abstract: AIMS: The molecular genetic mechanisms underlying postoperative nausea and vomiting (PONV) in the brain have not been fully elucidated. This study aimed to determine the changes in whole transcriptome in the nucleus of the solitary tract (NTS) in an animal model of PONV, to screen a drug candidate and to elucidate the molecular genetic mechanisms of PONV development. METHODS: Twenty‐one female musk shrews were assigned into three groups: the Surgery group (shrew PONV model, n = 9), the Sham group (n = 6), and the Naïve group (n = 6). In behavioral studies, the main outcome was the number of emetic episodes. In genetic experiments, changes in the transcriptome in the NTS were measured. In a separate study, 12 shrews were used to verify the candidate mechanism underlying PONV. RESULTS: A median of six emetic episodes occurred in both the Sham and Surgery groups. Whole‐transcriptome analysis indicated the inhibition of the GABA(B) receptor‐mediated signaling pathway in the PONV model. Baclofen (GABA(B) receptor agonist) administration eliminated emetic behaviors in the shrew PONV model. CONCLUSIONS: Our findings suggest that the GABA(B) receptor‐mediated signaling pathway is involved in emesis and that baclofen may be a novel therapeutic or prophylactic agent for PONV. Continued on ES/IODE ➡️ https://etcse.fr/Ck8j ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

My latest article on the potential of xenotransplantation 🧬🐖🫀🫁

This study aimed to examine myocardial damage at the molecular level in coronary bypass surgery patients, focusing on autophagy and apoptosis mechanisms. It found no significant difference in myocardial protection between Custodiol cardioplegia (CC) and Blood cardioplegia (BC) solutions, despite variations in BECLIN and CASPASE gene expressions in myocardial tissues. #Apoptosis #Cardioplegia #Custodiol

This study aimed to examine myocardial damage at the molecular level in coronary bypass surgery patients, focusing on autophagy and apoptosis mechanisms. It found no significant difference in myocardial protection between Custodiol cardioplegia (CC) and Blood cardioplegia (BC) solutions, despite variations in BECLIN and CASPASE gene expressions in myocardial tissues. #Apoptosis #Cardioplegia #Custodiol

Bayer Innovation in Kidney Transplants The shortage of kidneys contributes to the existence of a black market for organs, which operates through extensive criminal networks. By addressing the shortage, we can also address this issue. Additionally, pharmaceutical companies could address this issue in a preventable manner by helping the pre-made food industry to reduce / replace the use of harmful chemicals for food preservation. Currently, the high sodium content in pre-made food poses a significant risk to people's health. In terms of organ transplants, it is crucial to continue educating patients about the vital role of antibody rejection medication. A few years ago, I learned that the majority of organ transplant patients survive the surgery, thanks to the use of robotics. However, a significant number of patients die within 5 years because they stop taking the anti-rejection medications. Because questions arise along the treatment. We ZIPPYAR thought about it by providing s platform for patients engagement directly from their medication to increase treatment adherence.

First Pig-to-Human Liver Transplant Recipient 'Doing Very Well' A 71-year-old man in China has become the first living person to receive a liver transplant from a genetically modified pig, marking a significant milestone in medical science. The procedure, led by Sun Beicheng at the First Affiliated Hospital of Anhui Medical University, has shown promising results, with the patient reportedly "doing very well" more than two weeks post-surgery. This liver transplant is part of an ongoing exploration of xenotransplantation, where organs from genetically modified pigs are used to address the shortage of human donor organs. Since early 2022, surgeons have transplanted pig hearts, kidneys, and a thyroid into four people, with mixed outcomes. The latest success provides valuable insights and hope for the future of organ transplantation. “This is very exciting news,” says Burcin Ekser, a transplant surgeon at Indiana University School of Medicine, highlighting the potential advancements this successful transplant could lead to. #Transplantation #MedicalInnovation #Xenotransplantation #HealthcareAdvancements #GeneticModification https://lnkd.in/dFrWRQTc

Historic milestone reached in the global need for kidney transplants: our portfolio company eGenesis, Inc. today announced the first-ever successful transplantation of a genetically engineered porcine kidney into a living human recipient. “This successful procedure heralds a new era in medicine in which we have the potential to eliminate organ supply as a barrier to transplantation and realize our vision that no patient dies waiting for an organ,” - Michael Curtis Ph.D., CEO of eGenesis. The patient that enabled this scientific breakthrough suffers from end-stage renal disease and lacks other therapeutic options. eGenesis donor kidney carried three classes of gene edits: (1) knock out of three genes involved in hyperacute rejection (2) insertion of seven human transgenes involved in the regulation of pathways that modulate rejection (3) inactivation of the endogenous retroviruses in the porcine genome Huge congratulations to the entire eGenesis, Inc. team and the clinical team at the Massachusetts General Hospital that performed the surgery. Read more: https://lnkd.in/dZ7rCJQx

A Medical Marvel: World's First Genetically-Edited Pig Kidney Transplant In a groundbreaking medical procedure, Massachusetts General Hospital has achieved a world-first by successfully transplanting a genetically-edited pig kidney into a 62-year-old man with end-stage kidney disease. This pioneering surgery not only marks a major milestone in organ transplantation but also opens new doors in addressing the global organ shortage crisis. By utilizing CRISPR-Cas9 technology for genetic editing, this achievement showcases the potential of xenotransplantation and the power of innovative collaboration in advancing medical science. What do you think the implications of this medical breakthrough could be for the future of organ transplantation? Takeaway: The successful transplantation of a genetically edited pig kidney into a human recipient is a testament to the relentless pursuit of medical innovation, offering hope to millions awaiting lifesaving transplants worldwide. #MedicalInnovation #Xenotransplantation #CRISPR #OrganDonation #Transplantation